| Term | Definition |
|---|
| Prevacid | Type - Delayed-release capsules, enteric coated granules; MOA - Granules release drug in intestine, drug absorbed and shows effect in stomach |
| Lamictal XR | Type - extended release tablets, enteric coated; MOA - enteric coated and contain a modified release formulation in center of tablet, specially designed opening in enteric coating on both side of table that utilizes DiffCORE, allowing a controlled release of drug in acid of stomach to bloodstream |
| Budeprion SR | Type - extended release tablets; MOA tab - oral extended release |
| Protonix | Type - delayed release tablets, enteric coated; MOA - enteric-coated tablets begins to release drug only after leaving the stomach |
| Depakote | Type - delayed release tablets; MOA - tablets dissociated into valproate ion in GI tract |
| Allegra D 12 Hour | Type - Extended release tablets, peach colored film coating; MOA - 2 layer tablet with immediate release fexofenadine, and tan layer with film coating of pseudoephedrine HCl |
| BenzaClin | Type - Topical gel; MOA - absorbs into the skin |
| Budeprion XL | Type - extended release tablets, insoluble shell eliminated in feces; MOA - extended release tablets, releases drug, shell remains |
| Detrol LA | Type - extended release capsules, beaded capsule; MOA - slow dissolving beaded capsule controlled release |
| Glipizide XL | Type - osmotic delivery, extended release tablet; MOA - osmotically active drug core surrounded by semipermeable membrane, core divided into 2 layers, one with drug and a push layer of NaCl components, GI water enter tablet, pressure increases and pushes against dissolving drug layer, releasing drug thru laser drilled orifice in membrane on drug side of tablet, drug delivery is constant as long as osmotic gradient is until drug runs out |
| Nuvaring | Type - extended release insert; MOA - vaginal ring releases drug over 3 weeks at constant rate |
| Ortho Evra | Type - Transdermal extended release patch, matrix type; MOA - matrix type transdermal patch of 3 layers, backing layer for support and protection from environment, middle layer for drug, 3rd layer for release liner that protects adhesive layer during storage |
| Enablex | Type - extended release tablets, darifenacin |
| Sular | Type - extended release tablets; MOA - external coat and internal core which both contain drug, coat is slow release, core is fast release |
| Nexium | Type - delayed release capsules, enteric coated granules; MOA - degrades rapidly in acid, oral suspension contains enteric coated granules used in capsules |
| Aldara | Type - oil in water vanishing cream; MOA - topical |
| Allegra D 24 Hour | Type - immediate and extended tablet; MOA - 2 layer tablet with immediate release fexofenadine and clear film coating on pseudoephedrine layer |
| Oxycontin | Type - extended release tablets; MOA - 2 layer tablet |
| Paxil CR | Type - enteric coated; MOA - film coating of polymer, one layer contains degradable barrier which degrades in the upper GI while the 2nd layer is delayed to be released in the lower part of GI, coating allows minimal release in stomach |
| Focalin XR | Type - extended release capsules; MOA - bimodel release profile using SODAS technology, each bead filled capsul contains half dose immediate release beads and half enteric coated delayed release beads |
| Ambien CR | Type - 2 layer coated tablet; MOA - one layer releases immediately, another layer allows slower release of additional drug |
| Uroxatral | Type - extended release tablet |
| Concerta | Type - osmotic delivery system, extended release tablet; MOA - osmotically active core surrounded by semipermeable membrane, core divided into 2 layers of drug and push NaCl layers, water permeates membrane and enters push layer which pushes the dissolving drug out thru a hole in membrane of tablet |
| Humulin 70/30 | Type - insulin injection; MOA - subcutaneous |
| Lantus SoloSTAR | Type - insulin injection; MOA - subcutaneous, slower prolonged absorption |
| Adderall XR | Type - 2 types of beads; MOA - two types of drug-containing beads designed to give double pulsed delivery of amphetamines |
| Coreg CR | Type - gel capsule, microparticles, layered and coated; MOA - hard gelatin capsules for immediate release and microparticles for controlled release, layered and coated for delayed release |
| Asacol | Type - delayed release tablet, protective coat; MOA - tablets have protective coat consisting of acrylic based resins, inner layer dissolves at pH 7 or greater |
| Dilantin | Type - extended release tablet |
| Effexor XR | Type - diffusion based; MOA - diffusion thru coating membrane on spheroids and is not pH dependent |
| Premarin Vaginal Cream | Type - sustained release cream; MOA - drug release is delayed by skin absorption |
| Niaspan | Type - enteric coated, film coated tablet; MOA - film coating allows release of drug in lower part of GI tract, and minimal release in stomach, releases in small intestine |
| Tussionex | Type - pennkinetic system; MOA - pennkinetic system combines ion exchange polymer matrix with diffusion rate-limiting permeable coating |
| Wellbutrin XL | Type - extended release tablets; MOA - insoluble yellow shell of XL tablet may remain intact during GI transit and eliminated in feces |
| Toprol XL | Type - extended release tablets; MOA - tablets comprise of metoprolol in multiple controlled release pellets acting as a separate drug delivery unit over dosage interval |
| Vivelle-DOT | Type - transdermal patch; MOA - 3 layer patch of translucent polyolefin film, adhesive formulation of estradiol, acrylic adhesive, silicone adhesive, oleyl alcohol, NF, povidine, USP and dipropylene glycol and a polyester release liner attached to adhesive surface and must be removed |
| Differin | Type - Gel; MOA - sustained release gel |
| Klor-con | Type - extended release tablets; MOA - tablet containing individually microencapsulated crystals which disperse upon tablet disintegration |
| Androgel | Type - sustained release gel; MOA - hydroalcoholic formulation that dries quickly on skin and serves as reservoir for sustained release |
| Ultram ER | Type - extended release tablets; MOA - insoluble shell of extended release tablet may remain intact during GI transit and eliminated in feces |
| Catapres-TTS | Type - patch; MOA - energy for drug release is from concentration gradient existing between a saturated solution of drug in the system and much lower concentration prevailing in the skin |
| Lidoderm | Type - patch; MOA - skin as barrier for continuous absorption |
| Cymbalta | Type - delayed release capsules; MOA - capsule contains enteric-coated pellets designed to prevent degradation of drug in acid of stomach |
Combine with other sets
Share on Facebook
Share on MySpace
!